Mylan/Gilead, AbbVie/MPP boost access to HIV medicines
This article was originally published in Scrip
Executive Summary
Access to Gilead Sciences's next-generation HIV medicines and pediatric formulations of AbbVie's biggest-selling antiviral therapy will increase in developing countries under new agreements with commercial and nonprofit partners, Mylan and the Medicines Patent Pool (MPP).
You may also be interested in...
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.